BioCryst Pharmaceuticals (BCRX)
(Delayed Data from NSDQ)
$7.52 USD
-0.33 (-4.20%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $7.51 -0.01 (-0.13%) 7:58 PM ET
1-Strong Buy of 5 1
F Value C Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for BioCryst Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 391 | 426 | 511 | 303 | 138 |
Receivables | 57 | 51 | 29 | 9 | 22 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 29 | 28 | 16 | 7 | 0 |
Other Current Assets | 20 | 13 | 10 | 6 | 4 |
Total Current Assets | 496 | 517 | 566 | 324 | 164 |
Net Property & Equipment | 8 | 9 | 9 | 7 | 7 |
Investments & Advances | 0 | 18 | 7 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 13 | 7 | 6 | 4 | 4 |
Total Assets | 517 | 550 | 588 | 335 | 175 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 30 | 30 |
Accounts Payable | 21 | 14 | 28 | 19 | 14 |
Current Portion Long-Term Debt | 24 | 0 | 0 | 0 | 9 |
Current Portion Capital Leases | 2 | 2 | 2 | 1 | 1 |
Accrued Expenses | 103 | 88 | 73 | 34 | 21 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 1 | 1 | 22 | 17 |
Total Current Liabilities | 150 | 106 | 104 | 106 | 92 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 811 | 733 | 585 | 244 | 41 |
Non-Current Capital Leases | 3 | 6 | 6 | 4 | 3 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 972 | 845 | 695 | 354 | 137 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 2 | 2 | 2 | 2 | 2 |
Capital Surplus | 1,222 | 1,158 | 1,099 | 1,002 | 877 |
Retained Earnings | -1,681 | -1,455 | -1,208 | -1,023 | -841 |
Other Equity | 1 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -456 | -295 | -107 | -19 | 38 |
Total Liabilities & Shareholder's Equity | 517 | 550 | 588 | 335 | 175 |
Total Common Equity | -456 | -295 | -107 | -19 | 38 |
Shares Outstanding | 204.80 | 186.40 | 178.80 | 176.50 | 148.30 |
Book Value Per Share | -2.22 | -1.58 | -0.60 | -0.11 | 0.26 |
Fiscal Year End for BioCryst Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 338 | 391 | 399 | 412 |
Receivables | NA | 61 | 57 | 54 | 58 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 30 | 29 | 30 | 27 |
Other Current Assets | NA | 18 | 20 | 20 | 14 |
Total Current Assets | NA | 447 | 496 | 502 | 511 |
Net Property & Equipment | NA | 8 | 8 | 9 | 8 |
Investments & Advances | NA | 0 | 0 | 0 | 3 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 13 | 13 | 11 | 7 |
Total Assets | NA | 468 | 517 | 523 | 530 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 0 | 21 | 11 | 14 |
Current Portion Long-Term Debt | NA | 26 | 24 | 0 | 0 |
Current Portion Capital Leases | NA | 2 | 2 | 2 | 3 |
Accrued Expenses | NA | 79 | 103 | 77 | 75 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 12 | 0 | 1 | 2 |
Total Current Liabilities | NA | 120 | 150 | 91 | 94 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 813 | 811 | 833 | 819 |
Non-Current Capital Leases | NA | 3 | 3 | 10 | 6 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 944 | 972 | 934 | 919 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 2 | 2 | 2 | 2 |
Capital Surplus | NA | 1,238 | 1,222 | 1,206 | 1,192 |
Retained Earnings | NA | -1,717 | -1,681 | -1,619 | -1,583 |
Other Equity | NA | 1 | 1 | 1 | 1 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | -476 | -456 | -411 | -389 |
Total Liabilities & Shareholder's Equity | NA | 468 | 517 | 523 | 530 |
Total Common Equity | 0 | -476 | -456 | -411 | -389 |
Shares Outstanding | 206.30 | 206.30 | 204.80 | 189.40 | 189.40 |
Book Value Per Share | 0.00 | -2.31 | -2.22 | -2.17 | -2.05 |